Self-renewal culture system for maintaining stability of liver progenitor cells for long time in vitro, culture method and application

By using 7SCLS culture medium combined with PI3K agonists and other combinations in vitro, the problem of self-renewal of liver progenitor cells is solved, and the long-term stable self-renewal and bidirectional differentiation potential of liver progenitor cells is achieved, and the treatment of liver disease and drug development is provided. source of cells.

CN118979007APending Publication Date: 2024-11-19THE NAVAL MEDICAL UNIV OF PLA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410844140.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-27
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art is difficult to achieve stable self-renewal of liver progenitor cells in vitro, limiting the cell source and therapeutic effect of liver disease cell therapy.

Method used

Using a self-renewal medium containing PI3K agonist, TGFβ inhibitor, GSK-3 inhibitor, LPA and S1P, activates the PI3K signaling pathway and forms 7SCLS medium for maintaining long-term stable self-renewal of liver progenitor cells in vitro .

Benefits of technology

It has achieved long-term stable self-renewal of mouse and human liver progenitor cells, has the potential for bidirectional differentiation to hepatocytes and bile duct epithelial cells, and provides a stable source of cellular for liver disease treatment and drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979007A_ABST
    Figure CN118979007A_ABST
Patent Text Reader

Abstract

The invention provides a self-renewal culture system for maintaining liver progenitor cells to be stable for a long time in vitro, a culture method and application, the culture system comprises a basic culture medium and an in-vitro maintenance factor combined with the basic culture medium for use, the in-vitro maintenance factor comprises 0.01 to 20 [mu] M of a PI3K agonist, 0.1 to 50 [mu] M of a TGF [beta] inhibitor, 0.1 to 10 [mu] M of a GSK-3 inhibitor, 0.1 to 20 [mu] M of LPA and 0.01 to 5 [mu] M of S1P. Through experiments, stable self-renewal of the mouse embryonic liver progenitor cells can be maintained in vitro by using the research method disclosed by the invention, the mouse liver progenitor cells can be passaged for at least twenty generations, and the cultured mouse liver progenitor cells have bidirectional potential of differentiating to liver cells and bile duct epithelial cells; and the self-renewal of liver progenitor cells derived from human embryonic stem cells can be maintained in vitro. Therefore, the research has important application potentials and advantages in the aspect of liver disease treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedical engineering, and relates to a self-renewal culture system capable of maintaining the stability of liver progenitor cells in vitro for a long period of time, a culture method and an application thereof. Background Art

[0002] The liver is a core organ for maintaining homeostasis in the body, playing a wide range of roles such as metabolism, glycogen storage, drug detoxification, synthesis of various plasma proteins, and bile secretion. Approximately 2 million people die from liver disease each year worldwide. For end-stage liver disease, liver transplantation is the only treatment, however, the shortage of donor organs and the need for lifelong immunosuppression severely limit the clinical application of this treatment. Hepatocyte transplantation is an effective method for treating certain liver metabolic disorders and chronic liver damage. Compared with solid organ transplantation, it has the advantages of less invasiveness, low cost, multiple inputs, and fewer complications. Since the first human hepatocyte transplantation for the treatment of cirrhosis in 1992, there have been more than 100 clinical reports, especially for the treatment of liver metabolic disorders. Hepatocyte transplantation has shown good patient tolerance and varying degrees of patient treatment benefits, and even long-term disease remission.

[0003] Hepatocyte transplantation can prolong the life of patients and reduce the mortality rate during the waiting period for liver organ transplantation, and it has important clinical value for the treatment of acute liver failure. However, there are also a series of bottleneck problems that need to be solved in the treatment of liver diseases using hepatocyte transplantation. At present, the hepatocytes used in clinical studies usually come from livers that are not suitable for organ transplantation. The source and quality of hepatocytes seriously limit the systematic evaluation and application of this treatment method. Achieving self-renewal of liver progenitor cells will provide a stable cell source for cell therapy of liver diseases, and because liver progenitor cells have the potential to differentiate into hepatocytes, self-renewing liver progenitor cells make it possible to prepare functional hepatocytes in large quantities in vitro. Functional hepatocytes can not only be used as seed cells for cell therapy, but also can be used to prepare in vitro artificial liver support systems, as well as for in vitro drug development and toxicological evaluation. Therefore, it is of great significance to establish an expansion system for liver progenitor cells and achieve stable self-renewal of liver progenitor cells in vitro. Summary of the invention

[0004] The present invention is made to solve the above-mentioned problem, and provides a preliminary solution to the problem that it is currently impossible to obtain liver progenitor cells that can stably self-renew in vitro, thereby achieving stable self-renewal of liver progenitor cells in vitro.

[0005] The first aspect of the present invention provides a self-renewal culture system for maintaining stable liver progenitor cells in vitro for a long time, comprising a basal culture medium and an in vitro maintenance factor used in combination with the basal culture medium. The in vitro maintenance factor includes 0.01-20 μM PI3K agonist, 0.1-50 μM TGFβ inhibitor, 0.1-10 μM GSK-3 inhibitor, 0.1-20 μM LPA, and 0.01-5 μM S1P, which activates the PI3K signaling pathway to achieve self-renewal of liver progenitor cells under full chemical small molecule conditions.

[0006] Preferably, the basal culture medium is DMEM / F12 liquid basal culture medium;

[0007] 740Y-P, IGF1, IGF2, PDGF, or one or more

[0008] In a specific embodiment of the present invention, the PI3K agonist refers to 740Y-P, the TGFβ inhibitor refers to SB431542, and the GSK-3 inhibitor refers to CHIR99021, which are combined with LPA and S1P and added to the DMEM / F12 liquid basal culture medium to form a self-renewal culture system, named 7SCLS culture medium.

[0009] In the 7SCLS culture medium, the components and their optimal concentrations are as follows: 740Y-P content is 0.5 μM, SB431542 content is 2 μM, CHIR99021 content is 3 μM, LPA content is 5 μM, and S1P content is 0.5 μM.

[0010] Using the 7SCLS medium, mouse liver progenitor cells can be passaged for at least twenty generations, and mouse liver progenitor cells cultured under 7SCLS conditions have the bidirectional potential to differentiate into hepatocytes and bile duct epithelial cells. 7SCLS culture conditions can also maintain the self-renewal of liver progenitor cells derived from human embryonic stem cells in vitro.

[0011] Although the above components are used for experiments in the specific embodiments of the present invention, each component is not limited to the above specific components. For example, among the PI3K agonists, 0.5 μM 740Y-P is selected for experiments, but the remaining components can also achieve the corresponding functions. The same is true for the selection of ingredients in other components.

[0012] The second aspect of the present invention provides a method for maintaining the stability of liver progenitor cells in vitro for a long time using the above-mentioned culture system, comprising the following steps: culturing the isolated or induced mammalian liver progenitor cells in vitro in a self-renewal culture system, and after 2-3 passages, the liver progenitor cells are gradually purified due to their growth advantages, and then passaged every 3-4 days at a ratio of 1:6 using Accutase cell digestion solution.

[0013] Preferably, the mammalian liver progenitor cells are selected from mouse, rat or human liver progenitor cells;

[0014] Mouse or rat liver progenitor cells are isolated from fetal liver. The specific steps are as follows: transfer the fetal liver to 1 mL Accu-tase digestion enzyme, use a needle to separate the tissue and digest it at 37°C for 10 minutes; filter out the connective tissue, collect the cells by centrifugation, resuspend the cells with self-renewal medium, and evenly spread the fetal liver cells from each embryo into each well coated with Matrigel matrix gel; change the medium 2 hours after inoculation to remove most of the suspended cells including blood cells; after 2-3 passages, the liver progenitor cells are gradually purified due to their growth advantage;

[0015] Human liver progenitor cells were induced from human embryonic stem cells.

[0016] The culture system of the present invention can realize the expansion of liver progenitor cells derived from human pluripotent stem cells and can maintain the stable self-renewal of mouse liver progenitor cells. The cultured liver progenitor cells have the bidirectional potential to differentiate into hepatocytes and bile duct epithelial cells.

[0017] Therefore, the third aspect of the present invention provides the use of liver progenitor cells obtained by the above-mentioned culture method in liver tissue engineering, liver failure treatment cells and in vitro drug screening for liver diseases.

[0018] The beneficial protection and effects of the present invention are as follows:

[0019] Through experiments, the research method of the present invention can maintain the stable self-renewal of mouse embryonic liver progenitor cells in vitro. Mouse liver progenitor cells can be passaged for at least twenty generations under 7SCLS culture conditions, and the cultured mouse liver progenitor cells have the bidirectional potential to differentiate into hepatocytes and bile duct epithelial cells; in addition, 7SCLS culture conditions can also maintain the self-renewal of liver progenitor cells derived from human embryonic stem cells in vitro. The above results show that this study has important application potential and advantages in the treatment of liver diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The experimental results of the fifth generation of mTmG mouse liver progenitor cells cultured under 7SCLS conditions. A is a visible light photo of mTmG mouse liver progenitor cells expanded to the fifth generation in 7SCLS medium; B and C are fluorescence photos of membrane-localized red fluorescent protein (mTomato); DF are immunofluorescence staining of liver progenitor cell markers AFP / HNF4A (D, E and F are the same cell field of view).

[0021] Figure 2The results of laboratory analysis of mouse liver progenitor cells maintained under 7SCLS culture conditions to the 15th generation. Mouse liver progenitor cells were cultured and expanded to the 15th generation under 7SCLS conditions. Immunofluorescence staining showed that the cells expressed marker molecules of liver progenitor cells such as AFP (A), HNF4A (B), CK19 and DLK1 (C and D), epithelial cell marker E-Cadherin and cell proliferation marker Ki-67 (E and F), indicating that the cells maintained the characteristics of liver progenitor cells after long-term passage under 7SCLS conditions.

[0022] Figure 3 The growth curve of mouse liver progenitor cells cultured in 7SCLS and the experimental results of chromosome analysis. A is the growth curve of liver progenitor cells under ESCLS and 7SCLS conditions; B is the chromosome photo of liver progenitor cells under 7SCLS culture conditions.

[0023] Figure 4 Results of the analysis of the mechanism of 740Y-P maintaining the self-renewal of liver progenitor cells. AC are immunofluorescence staining of Ki-67 in liver progenitor cells under 7SCLS, 7SCLS+LY294002 and SCLS conditions; D is the quantitative analysis of immunofluorescence staining of Ki-67 in mouse liver progenitor cells under different culture conditions; E is the Western Blot analysis of AKT and p-AKT (phosphorylated AKT) levels in liver progenitor cells after treatment with SCLS, 7SCLS, ESCLS and 7SCLS+LY294002 (2μM).

[0024] Figure 5 The experimental results of inducing human embryonic stem cells to differentiate into liver progenitor cells. A is the technical route for the differentiation of human embryonic stem cells into liver progenitor cells; B shows that HUES9 cells (OCT4 / SSEA4 positive, Day 0) differentiate into primitive streak (TBXT positive, Day 2), endoderm (CXCR4 / SOX17 positive, Day 5), and finally differentiate into AFP and HNF4A positive liver progenitor cells on the 11th day.

[0025] Figure 6 The results of the analysis of human liver progenitor cells derived from human pluripotent stem cells expanded by 7SCLS. Immunofluorescence staining of human liver progenitor cells at the 10th passage under 7SCLS conditions showed that the cells expressed marker molecules of liver progenitor cells such as AFP and HNF4A (A), DLK1 (B), EpCAM (C), epithelial cell marker E-Cadherin (D), cell proliferation marker Ki-67 and stem cell marker CD133 (E), and β-Catenin (F).

[0026] Figure 7The results of the bidirectional differentiation potential analysis experiment of liver progenitor cells expanded by 7SCLS. A is the immunofluorescence staining of hepatocyte functional molecules ALB, HNF4A and CYP3A4 in mouse liver progenitor cells cultured with 7SCLS conditions and inducing with HOD medium for two weeks; B is the expression of hepatocyte functional genes and YAP downstream genes detected by quantitative PCR after HOD-induced liver progenitor cells differentiated into hepatocytes. The 7SCLS group represents mouse liver progenitor cells cultured with 7SCLS conditions, the HOD group represents liver progenitor cells induced with HOD medium for two weeks, and the FH group represents freshly isolated hepatocytes; C is the immunofluorescence staining of visible light and bile duct marker molecules such as CK19, Integrinα6 and Integrinβ4 in the bile duct-like structure formed by liver progenitor cells. DETAILED DESCRIPTION

[0027] The present invention is now described in detail with reference to the embodiments, but the implementation of the present invention is not limited thereto.

[0028] The reagents and raw materials used in the present invention are all commercially available or can be prepared according to literature methods. The experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are calculated by weight.

[0029] Example 1: Acquisition of mouse liver progenitor cells

[0030] SPF grade C57BL / 6J mice (SLAC laboratory in Shanghai) at about 12 days of pregnancy were selected and killed by spinal dislocation; embryos were separated and removed in a clean bench and washed in PBS, and the red fetal liver was peeled and picked out with a syringe needle; the fetal liver was transferred to 1mL Accutase digestion enzyme (Invitrogen, USA), and the tissue was separated with a needle and digested at 37℃ for 10 minutes; connective tissue was filtered out, cells were collected by centrifugation, and cells were resuspended in 7SCLS medium. The fetal liver cells obtained from each embryo were evenly spread in each well coated with Matrigel matrix gel; the medium was changed 2 hours after inoculation to remove most of the suspended cells including blood cells; after 2-3 passages, liver progenitor cells were gradually purified due to growth advantages. Subsequently, Accutase cell digestion solution was usually used for passage at a ratio of 1:6 every 3-4 days.

[0031] Example 2: 7SCLS culture conditions can maintain stable self-renewal of mouse liver progenitor cells

[0032] 1. Identification and proliferation analysis of liver progenitor cells

[0033] Rosa26 was isolated by the same method as in Example 1 loxP-mTom-stop-loxP–mGFPThe liver progenitor cells of (mTmG) reporter mice (Jackson Laboratory, Cat#007576) were used for corresponding experiments and analyses.

[0034] Liver progenitor cells from mTmG mice (all cells of this mouse constitutively express the membrane-localized red fluorescent protein mTomato) expanded to the fifth generation in 7SCLS medium. Liver progenitor cells have a typical cobblestone epithelial cell morphology ( Figure 1 A), relatively uniform expression of mTomato ( Figure 1 B, 1C) and liver progenitor cell markers alpha-fetoprotein (α1-fetoprotein, AFP) and HNF4A ( Figure 1 D-1F).

[0035] Mouse liver progenitor cells are usually passaged every 3-4 days at a ratio of 1:6 using Accutase under 7SCLS conditions. The cells can be stably passaged for more than 20 generations. Figure 4 The immunofluorescence staining results of mouse liver progenitor cells expanded to the 15th generation are shown. The cells express marker molecules of liver progenitor cells such as AFP ( Figure 2 A), HNF4A ( Figure 2 B), cytokeratin 19 (CK19) and DLK1 (delta like non-canonical Notch ligand 1) ( Figure 2 C, 2D), epithelial cell marker E-Cadherin and cell proliferation marker Ki-67 ( Figure 2 E, 2F). Growth curve analysis showed that the mouse liver progenitor cells under the 7SCLS culture conditions had a similar cell proliferation process as the ESCLS culture conditions (protein and small molecule combination of EGF, SB431542, CHIR99021, LPA and S1P) in the previous study of the project team ( Figure 3 A), Chromosome analysis showed that liver progenitor cells under 7SCLS conditions still maintained a normal chromosome number at the 15th passage ( Figure 3 B). The above results indicate that 7SCLS can maintain the stable self-renewal of mouse liver progenitor cells.

[0036] 2. Analysis of the mechanism of 740Y-P maintaining the self-renewal ability of liver progenitor cells

[0037] The liver progenitor cells of C57BL / 6 mice were isolated by the same method as in Example 1, and the corresponding experiments and analyses were performed.

[0038] 740Y-P is a chemically synthesized PI3K agonist. Next, we verified whether 740Y-P maintains the self-renewal of liver progenitor cells through the PI3K signaling pathway. LY294002 is a PI3K inhibitor. Adding LY294002 to 7SCLS conditions can significantly reduce the positive rate of Ki-67 in liver progenitor cells. Removing 740Y-P from the culture medium (SCLS) also leads to a decrease in the positive rate of Ki-67 ( Figure 4 A-4D); Western Blot demonstrated that 740Y-P can activate the PI3K / AKT signaling pathway, and this effect can be blocked by LY294002 ( Figure 4 E). The above results verified that 740Y-P can maintain the self-renewal of liver progenitor cells by activating the PI3K signaling pathway.

[0039] Example 3: 7SCLS culture conditions can expand liver progenitor cells derived from human pluripotent stem cells

[0040] 1. Acquisition of human liver progenitor cells

[0041] First, embryonic stem cells (H1 and HUES9 cell lines) were induced to differentiate into human liver progenitor cells, and then expanded and cultured under 7SCLS conditions. The induction and differentiation process of embryonic stem cells into liver progenitor cells is referred to Figure 5 As shown in A: Human embryonic stem cells (H1 and HUES9 cell lines) differentiate into liver progenitor cells through primitive streak, endoderm, primitive gut and other stages (for details of the differentiation culture system at each stage, please refer to the experimental materials and methods section); Figure 5 B shows that HUES9 cells (OCT4 / SSEA4 positive) differentiated sequentially into primitive streak (TBXT positive), endoderm (CXCR4 / SOX17 positive), and finally into AFP and HNF4A positive liver progenitor cells on day 11.

[0042] 2. Identification and proliferation analysis of human liver progenitor cells under 7SCLS culture conditions

[0043] Human pluripotent stem cell-derived liver progenitor cells were expanded using 7SCLS conditions, and it was found that 7SCLS can also effectively maintain the self-renewal of human embryonic stem cell-derived liver progenitor cells. Figure 6 The results showed that human liver progenitor cells passaged to passage 10 under the culture conditions expressed marker molecules of liver progenitor cells such as AFP / HNF4A ( Figure 6 A) DLK1( Figure 6 B) EpCAM ( Figure 6 C), epithelial cell marker E-Cadherin ( Figure 6 D), cell proliferation marker Ki-67 and stem cell marker CD133 ( Figure 6E), the expression of β-Catenin is also characteristic of epithelial cells ( Figure 6 F). The above indicated that 7SCLS medium can stably expand liver progenitor cells derived from human pluripotent stem cells.

[0044] 3. Analysis of differentiation potential of human liver progenitor cells under 7SCLS culture conditions

[0045] The induction conditions containing HGF, OSM, Dex, SB431542 and Compound E (referred to as HOD medium) were used to induce liver progenitor cells to differentiate into hepatocytes. After two weeks of induction under HOD conditions, the mouse liver progenitor cells expanded by 7SCLS could differentiate into ALB and CYP3A4 positive hepatocytes, while the mouse liver progenitor cells before induction basically did not express the above hepatocyte functional molecules ( Figure 7 A). Quantitative PCR analysis confirmed that the expression of hepatocyte functional genes Alb, Hnf4a and transthyretin (Ttr) was upregulated in liver progenitor cells after HOD induction, but the expression levels of these genes were significantly lower than those in freshly isolated hepatocytes ( Figure 7 B); YAP activation inhibits hepatocyte function. Quantitative PCR analysis showed that the expression levels of YAP downstream target genes connective tissue growth factor (Ctgf) and cysteine-rich angiogenic inducer 61 (Cyr61) in HOD-induced differentiated hepatocytes were significantly higher than those in freshly isolated hepatocytes ( Figure 7 B). Liver progenitor cells cultured under 7SCLS conditions were digested into single cell suspensions and placed in 50% Matrigel for three-dimensional culture for one week. Liver progenitor cells can form bile duct-like structures ( Figure 7 C), Immunofluorescence staining showed that the tube-like structures formed after one week of three-dimensional culture expressed marker molecules of bile duct epithelium ( Figure 7 C), such as CK19, Integrinα6, and Integrinβ4. F-actin is mainly distributed on the inner surface of the tubular structure, similar to the natural bile duct ( Figure 7 C) The above results indicate that liver progenitor cells cultured under 7SCLS conditions have the bidirectional potential to differentiate into hepatocytes and biliary epithelial cells.

[0046] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.

Claims

1. An in vitro long-term stable self-renewal culture system for liver progenitor cells, characterized in that: The invention comprises a basal medium and an in vitro maintenance factor used in combination with the basal medium, Wherein, the in vitro maintenance factors include 0.01-20 μM PI3K agonist, 0.1-50 μM TGFβ inhibitor, 0.1-10 μM GSK-3 inhibitor, 0.1-20 μM LPA, and 0.01-5 μM S1P.

2. The in vitro long-term stable self-renewal culture system for liver progenitor cells according to claim 1, characterized in that: in, The basal culture medium is DMEM / F12 liquid basal culture medium; The PI3K agonist refers to one or more of 740Y-P, IGF1, IGF2, and PDGF; TGFβ inhibitor refers to SB431542; The GSK-3 inhibitor refers to CHIR99021.

3. The human pluripotent stem cell-derived spinal cord OLIG2 according to claim 1 + A neural progenitor cell induction and self-renewal culture system, characterized by: in, The in vitro maintenance factors include 0.5 μM PI3K agonist, 2 μM TGFβ inhibitor, 3 μM GSK-3 inhibitor, 5 μM LPA, and 0.5 μM S1P.

4. The human pluripotent stem cell-derived spinal cord OLIG2 according to claim 1 + A neural progenitor cell induction and self-renewal culture system, characterized by: in, The PI3K agonist is selected from 740Y-P, the TGFβ inhibitor is selected from SB431542, and the GSK-3 inhibitor is selected from CHIR99021.

5. A method for maintaining the stability of hepatic progenitor cells in vitro for a long term using the culture system according to any one of claims 1 to 4, characterized in that: The steps include: The isolated or induced mammalian liver progenitor cells are cultured in vitro in a self-renewal culture system. After 2-3 passages, the liver progenitor cells are gradually purified due to their growth advantage, and then passaged every 3-4 days at a ratio of 1:6 using Accutase cell digestion solution.

6. The method for maintaining the stability of liver progenitor cells in vitro for a long term in a culture system according to claim 5, characterized in that: in, The mammalian liver progenitor cells are selected from mouse, rat or human liver progenitor cells; Mouse or rat liver progenitor cells are isolated from fetal liver. The specific steps are as follows: transfer the fetal liver to 1 mL of Accutase digestion enzyme, use a needle to separate the tissue and digest it at 37°C for 10 minutes; filter out the connective tissue, collect the cells by centrifugation, resuspend the cells with self-renewal medium, and evenly spread the fetal liver cells from each embryo into each well coated with Matrigel matrix gel; change the medium 2 hours after inoculation to remove most of the suspended cells including blood cells; after 2-3 passages, the liver progenitor cells are gradually purified due to their growth advantage; Human liver progenitor cells were induced from human embryonic stem cells.

7. Use of the liver progenitor cells obtained by the culture method of claim 5 in liver tissue engineering, liver failure therapeutic cells and in vitro drug screening for liver diseases.